ASCO Annual Meeting

Patients with cancer who attended a molecular tumor board meeting reported higher levels of satisfaction afterward, according to study results…

CHICAGO —Modified FOLFOX chemotherapy plus active symptom control improved OS compared with active symptom control alone among patients with…

CHICAGO — An interim analysis of data from the phase 2 RAMIRIS trial suggests that a combination regimen of FOLFIRI plus ramucirumab is a…

CHICAGO — Administering chemotherapy 6 weeks before surgery for colon cancer was safe and reduced postoperative morbidity without adding to the…

CHICAGO — Pazopanib was associated with a significant improvement in PFS compared with placebo in patients with progressive carcinoid tumors…

CHICAGO — Bijal D. Shah, MD, associate professor in the department of malignant hematology at Moffitt Cancer Center, spoke with HemOnc…

CHICAGO — Kirk Shepard, MD, senior vice president, chief medical officer and head of global medical affairs for the oncology business group at…

CHICAGO — Patients with various subtypes of pretreated, metastatic sarcoma showed improved response rates and survival when treated on…

CHICAGO — Max S. Topp, MD, head of hematology at University Hospital of Wuerzburg, Germany, spoke with HemOnc Today at ASCO Annual…

CHICAGO — The combination of pyrotinib and capecitabine significantly prolonged PFS among patients with HER2-positive metastatic breast cancer…